Recent studies (June 2020) confirm that for adults over 40, a red spectrum light (LLLT or Low level light therapy) can help the functioning of mitochondria, “There was a 14% improvement in the ability to see colors, or cone color contrast sensitivity, for the entire two dozen participants.” (1)
How did I find out about this ? I purchased this LED light for a indoor fogponics garden from Amazon, and over the span of a few days, noticed my eyesight improving. I used the Red LED setting. I couldn’t believe it. So I started researching it, and sure enough, a recent study just confirmed what I actually experienced. I’m living proof that it indeed works. Please see the links at the end of the email showing the science behind this discovery. I’ll be updating with additional NASA links shortly.
- 45W Red LED Light Therapy Panel, Deep Red 660nm and Near Infrared 850nm LED Light Therapy Combo (buy on Amazon here https://amzn.to/3260sEG ) About $89. This unit is primarily for topical applications and aches and pains. It is too bright for eye use.
- * Best Buy * Grow Light, 80W Tri Head Timing 80 LED 9 Dimmable Levels Plant Grow Lights for Indoor Plants with Red Blue Spectrum (buy on Amazon here https://amzn.to/3gTwfwD ) About $30 – these are the LED lights I used and saw eyesight improvement. Use the RED LED setting only. This is the best unit available that I have used for the past few weeks with good results. Recommended buy. This is a plug-in model for US voltage, not recommended for travel, but perfect for home use (obviously you can use it to grow plants too).
- * Best Buy * Rechargeable travel size Red Light Therapy (buy on Amazon here https://amzn.to/3gQm3ow ) About $32. This is a unit that works well. I have used it daily. Recommended buy for travel, easily rechargeable.
- TENDLITE Red Light Therapy Device – FDA Cleared Advanced Medical Grade Technology. Travel size. (buy on Amazon here https://amzn.to/32fUIIu ) About $180. This device is too bright for eyes, but perfect for topical applications for aches and pains. I have purchased this device and use it for knee aches.
Pilots: If you’re like me (and over 40), you’re concerned about your day and night vision getting worse, and your glasses prescription getting stronger. Help your vision using this simple technique. It works. I’m a Commercial, B727 Flight Engineer, Instrument Rated pilot. So whether your a weekend warrior, fly commercial for a living, or a military pilot, do the research and try for yourself.
(1) Declining eyesight improved by looking at deep red light, Researchers found the 670nm light had no impact in younger individuals, but in those around 40 years and over, significant improvements were obtained. Cone colour contrast sensitivity (the ability to detect colours) improved by up to 20% in some people aged around 40 and over. Improvements were more significant in the blue part of the colour spectrum that is more vulnerable in ageing. Rod sensitivity (the ability to see in low light) also improved significantly in those aged around 40 and over, though less than colour contrast. https://www.sciencedaily.com/releases/2020/06/200629120241.htm
(2) Declining eyesight can be improved by looking at red light, pilot study says, “A few minutes of looking into a deep red light could have a dramatic effect on preventing eyesight decline as we age, according to a new study published this week in The Journals of Gerontology… You don’t need to use it for very long to start getting a strong result,” said lead author Glen Jeffery, a professor of neuroscience at University College London’s Institute of Ophthalmology.” https://www.cnn.com/2020/06/30/health/declining-eyesight-red-light-scn-wellness/index.html
(3) Can Looking at Deep Red Light Improve Declining Eyesight ? Staring at a deep red light for 3 minutes a day can significantly improve declining eyesight in people aged over 40 years, finds a new UK study, which is the first of its kind in humans. Scientists believe the discovery, published in the Journals of Gerontology , could signal the dawn of new affordable home-based eye therapies to help people with naturally declining vision. At around 40 years, human retinal cell ageing accelerates, leading to vision deterioration. https://www.medscape.com/viewarticle/933381
(4) Photobiomodulation for the treatment of retinal diseases |Photobiomodulation (PBM), also known as low level laser therapy, has recently risen to the attention of the ophthalmology community as a promising new approach to treat a variety of retinal conditions including age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, Leber’s hereditary optic neuropathy, amblyopia, methanol-induced retinal damage, and possibly others. This review evaluates the existing research pertaining to PBM applications in the retina, with a focus on the mechanisms of action and clinical outcomes. All available literature until April 2015 was reviewed using PubMed and the following keywords: “photobiomodulation AND retina”, “low level light therapy AND retina”, “low level laser therapy AND retina”, and “FR/NIR therapy AND retina”. In addition, the relevant references listed within the papers identified through PubMed were incorporated. The literature supports the conclusion that the low-cost and non-invasive nature of PBM, coupled with the first promising clinical reports and the numerous preclinical-studies in animal models, make PBM well-poised to become an important player in the treatment of a wide range of retinal disorders. Nevertheless, large-scale clinical trials will be necessary to establish the PBM therapeutic ranges for the various retinal diseases, as well as to gain a deeper understanding of its mechanisms of action. Keywords: photobiomodulation, low level laser therapy, age-related macular degeneration, retinopathy of prematurity, far-red to near-infrared, retinal degeneration, amblyopia, retinitis pigmentosa, methanol toxicity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768515/
(5) Aging retinal function is improved by near infrared light (670 nm) that is associated with corrected mitochondrial decline |Aging is associated with cellular decline and reduced function, partly mediated by mitochondrial compromise. However, aged mitochondrial function is corrected with near infrared light (670 nm) that improves their membrane potentials and adenosine triphosphate production and also reduces age-related inflammation. We ask if 670 nm light can also improve declining retinal function. Electroretinograms were measured in 2-, 7-, and 12-month old C57BL/6 mice. Significant age-related declines were measured in the photoreceptor generated a-wave and the postreceptoral b-wave. Seven- and 12-month-old mice were exposed to 670 nm for 15 minutes daily over 1 month. These showed significant improved retinal function in both waves of approximately 25% but did not reach levels found in 2-month-old animals. Our data suggest, 670 nm light can significantly improve aged retinal function, perhaps by providing additional adenosine triphosphate production for photoreceptor ion pumps or reduced aged inflammation. This may have implications for the treatment of retinal aging and age-related retinal disease, such as macular degeneration. Keywords: Retina, Aging, Mitochondria https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364001/
(6) Light Therapy: Is It Safe for the Eyes? | Objective: Light therapy has become an increasingly popular treatment for depression and a range of other neuropsychiatric conditions. Yet, concerns have been raised about the ocular safety of light therapy. Method: We conducted the first systematic review into the ocular safety of light therapy. A PubMed search on January 4, 2017, identified 6708 articles, of which 161 were full-text reviewed. In total, 43 articles reporting on ocular complaints and ocular examinations were included in the analyses. Results: Ocular complaints, including ocular discomfort and vision problems, were reported in about 0% to 45% of the participants of studies involving light therapy. Based on individual studies, no evident relationship between the occurrence of complaints and light therapy dose was found. There was no evidence for ocular damage due to light therapy, with the exception of one case report that documented the development of a maculopathy in a person treated with the photosensitizing antidepressant clomipramine. Conclusion: Results suggest that light therapy is safe for the eyes in physically healthy, unmedicated persons. The ocular safety of light therapy in persons with preexisting ocular abnormalities or increased photosensitivity warrants further study. However, theoretical considerations do not substantiate stringent ocular safety-related contraindications for light therapy. Keywords: chronobiology https://pubmed.ncbi.nlm.nih.gov/28891192/
(7) Low-Intensity Far-Red Light Inhibits Early Lesions That Contribute to Diabetic Retinopathy: In Vivo and In Vitro |Purpose. Treatment with light in the far-red to near-infrared region of the spectrum (photobiomodulation [PBM]) has beneficial effects in tissue injury. We investigated the therapeutic efficacy of 670-nm PBM in rodent and cultured cell models of diabetic retinopathy. Methods. Studies were conducted in streptozotocin-induced diabetic rats and in cultured retinal cells. Diabetes-induced retinal abnormalities were assessed functionally, biochemically, and histologically in vivo and in vitro. Results. We observed beneficial effects of PBM on the neural and vascular elements of retina. Daily 670-nm PBM treatment (6 J/cm2) resulted in significant inhibition in the diabetes-induced death of retinal ganglion cells, as well as a 50% improvement of the ERG amplitude (photopic b wave responses) (both P < 0.01). To explore the mechanism for these beneficial effects, we examined physiologic and molecular changes related to cell survival, oxidative stress, and inflammation. PBM did not alter cytochrome oxidase activity in the retina or in cultured retinal cells. PBM inhibited diabetes-induced superoxide production and preserved MnSOD expression in vivo. Diabetes significantly increased both leukostasis and expression of ICAM-1, and PBM essentially prevented both of these abnormalities. In cultured retinal cells, 30-mM glucose exposure increased superoxide production, inflammatory biomarker expression, and cell death. PBM inhibited all of these abnormalities. Conclusions. PBM ameliorated lesions of diabetic retinopathy in vivo and reduced oxidative stress and cell death in vitro. PBM has been documented to have minimal risk. PBM is noninvasive, inexpensive, and easy to administer. We conclude that PBM is a simple adjunct therapy to attenuate the development of diabetic retinopathy. Keywords: photobiomodulation, diabetic retinopathy, retinal ganglion cells https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668802/
(8) Wound Healing | Adjunctive 830 nm light-emitting diode therapy can improve the results following aesthetic procedures | Background: Aggressive, or even minimally aggressive, aesthetic interventions are almost inevitably followed by such events as discomfort, erythema, edema and hematoma formation which could lengthen patient downtime and represent a major problem to the surgeon. Recently, low level light therapy with light-emitting diodes (LED-LLLT) at 830 nm has attracted attention in wound healing indications for its anti-inflammatory effects and control of erythema, edema and bruising. Rationale: The wavelength of 830 nm offers deep penetration into living biological tissue, including bone. A new-generation of 830 nm LEDs, based on those developed in the NASA Space Medicine Laboratory, has enabled the construction of planar array-based LED-LLLT systems with clinically useful irradiances. Irradiation with 830 nm energy has been shown in vitro and in vivo to increase the action potential of epidermal and dermal cells significantly. The response of the inflammatory stage cells is enhanced both in terms of function and trophic factor release, and fibroblasts demonstrate superior collagenesis and elastinogenesis. Conclusions: A growing body of clinical evidence is showing that applying 830 nm LED-LLLT as soon as possible post-procedure, both invasive and noninvasive, successfully hastens the resolution of sequelae associated with patient downtime in addition to significantly speeding up frank wound healing. This article reviews that evidence, and attempts to show that 830 nm LED-LLLT delivers swift resolution of postoperative sequelae, minimizes downtime and enhances patient satisfaction. Keywords: Photobiomodulation, low level light therapy, wound healing, collagenesis, angiogenesis, hematoma, edema, erythema https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751092/
(9) Research progress about the effect and prevention of blue light on eyes |In recent years, people have become increasingly attentive to light pollution influences on their eyes. In the visible spectrum, short-wave blue light with wavelength between 415 nm and 455 nm is closely related to eye light damage. This high energy blue light passes through the cornea and lens to the retina causing diseases such as dry eye, cataract, age-related macular degeneration, even stimulating the brain, inhibiting melatonin secretion, and enhancing adrenocortical hormone production, which will destroy the hormonal balance and directly affect sleep quality. Therefore, the effect of Blu-rays on ocular is becoming an important concern for the future. We describe blue light’s effects on eye tissues, summarize the research on eye injury and its physical prevention and medical treatment. Keywords: blue light, ocular injury, prevention https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288536/
(10) The Science Behind Myopia | https://www.ncbi.nlm.nih.gov/books/NBK470669/
(11) The Wavelength Composition and Temporal Modulation of Ambient Lighting Strongly Affect Refractive Development in Young Tree Shrews | Conclusions: The incidence of myopia is increasing worldwide (Hrynchak et al., 2013; Sun et al., 2012). In addition, myopia is a major risk factor for eye disease, (Burton, 1989; Saw et al., 2005; Vongphanit et al., 2002; Zadnik, 2001) and has significant negative effects on the quality of life. (McCarty and Taylor, 2000; Roch-Levecq et al., 2008) The substantial hyperopia produced by the long-wavelength LEDs might eventually prove useful as a counter-measure against myopia. Interestingly, we recently have found that the red-light treatment can produce hyperopia in adolescent tree shrews that have completed normal emmetropization (Norton et al., 2016). Also, in young tree shrews, presenting the red light for as little as 2 hours per day slows the decrease in refraction toward emmetropia (Gawne et al., 2016). Conversely, the myopiagenic effect of the specific short-wavelength flicker used here raises the possibility that there may be similar stimuli present in some artificial lighting that should be avoided. Certainly, the dramatic effects observed here during early postnatal refractive development suggest that it is important to further explore the degree to which the chromatic and temporal content of ambient light may affect refractive state. Keywords: Myopia, Hyperopia, Vitreous Chamber, Longitudinal Chromatic Aberration, Optical Blur, Retinal signaling https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359068/
(12) Low-level light therapy of the eye and brain | Low-level light therapy (LLLT) using red to near-infrared light energy has gained attention in recent years as a new scientific approach with therapeutic applications in ophthalmology, neurology, and psychiatry. The ongoing therapeutic revolution spearheaded by LLLT is largely propelled by progress in the basic science fields of photobiology and bioenergetics. This paper describes the mechanisms of action of LLLT at the molecular, cellular, and nervous tissue levels. Photoneuromodulation of cytochrome oxidase activity is the most important primary mechanism of action of LLLT. Cytochrome oxidase is the primary photoacceptor of light in the red to near-infrared region of the electromagnetic spectrum. It is also a key mitochondrial enzyme for cellular bioenergetics, especially for nerve cells in the retina and the brain. Evidence shows that LLLT can secondarily enhance neural metabolism by regulating mitochondrial function, intraneuronal signaling systems, and redox states. Current knowledge about LLLT dosimetry relevant for its hormetic effects on nervous tissue, including noninvasive in vivo retinal and transcranial effects, is also presented. Recent research is reviewed that supports LLLT potential benefits in retinal disease, stroke, neurotrauma, neurodegeneration, and memory and mood disorders. Since mitochondrial dysfunction plays a key role in neurodegeneration, LLLT has potential significant applications against retinal and brain damage by counteracting the consequences of mitochondrial failure. Upon transcranial delivery in vivo, LLLT induces brain metabolic and antioxidant beneficial effects, as measured by increases in cytochrome oxidase and superoxide dismutase activities. Increases in cerebral blood flow and cognitive functions induced by LLLT have also been observed in humans. Importantly, LLLT given at energy densities that exert beneficial effects does not induce adverse effects. This highlights the value of LLLT as a novel paradigm to treat visual, neurological, and psychological conditions, and supports that neuronal energy metabolism could constitute a major target for neurotherapeutics of the eye and brain. Keywords: photobiomodulation, cytochrome oxidase, neurotherapeutics, retinal disease, neurological disease, cognitive and mood disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436183/
Keywords: pilot vision, FAA vision, FAA eyesight, airline pilots, eyesight requirements
military pilot eyesight, vision requirements for pilots, healthy eyes,
eyesight, pilot training, aviation, supplements for eyesight, pilot eyesight
supplements for eyes, macular degeneration, optometrist